2025 · Abstract/Manuscript · Abstract/Manuscript
54
Total Publications
13
Abstract/Manuscript
5
Oral Presentation
36
Poster Presentation
2025 · Abstract/Manuscript · Abstract/Manuscript
Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease.
Read more →2025 · Poster Presentation · Poster Presentation · Hepatology
Changes in The Fibrosis-4 (FIB-4) Score Accurately Reflects The Disease Trajectory of Metabolic Dysfunction Associated Steatotic Liver Disease.
Read more →2025 · Poster Presentation · Poster Presentation · Hepatology
Clinical Characteristics of Patients With Presumed MASLD Who Meet Met-ALD Criteria in the TARGET-NASH Cohort.
Read more →2025 · Poster Presentation · Poster Presentation · Hepatology
Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions.
Read more →2025 · Poster Presentation · Poster Presentation · Hepatology
Type 2 Diabetes and Obesity are The Main Metabolic Risk Factors for The Development of Cirrhosis in People with Metabolic Dysfunction Associated Steatohepatitis.
Read more →2024 · Poster Presentation · Poster Presentation · Hepatology
Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting.
Read more →2024 · Poster Presentation · Poster Presentation · Hepatology
Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status.
Read more →2024 · Poster Presentation · Poster Presentation · Hepatology
A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease.
Read more →2024 · Poster Presentation · Poster Presentation · Hepatology
Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort.
Read more →2024 · Poster Presentation · Poster Presentation · Hepatology
Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort.
Read more →2024 · Poster Presentation · Poster Presentation · Hepatology
Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups.
Read more →2024 · Poster Presentation · Poster Presentation · Hepatology
Use of sodium-glucose transport protein 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with MASLD in a real-world setting is associated with lower all-cause mortality.
Read more →2024 · Poster Presentation · Poster Presentation · Hepatology
Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH.
Read more →2024 · Poster Presentation · Poster Presentation · Hepatology
A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease.
Read more →2024 · Poster Presentation · Poster Presentation · Hepatology
Non-invasive tests as a prediction tool to assess MASH resolution score.
Read more →2024 · Poster Presentation · Poster Presentation · Hepatology
A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH.
Read more →2024 · Abstract/Manuscript · Abstract/Manuscript
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort.
Read more →2024 · Abstract/Manuscript · Abstract/Manuscript
High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.
Read more →2024 · Poster Presentation · Poster Presentation · Hepatology
Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH.
Read more →2024 · Oral Presentation · Oral Presentation · Hepatology
Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality.
Read more →2023 · Poster Presentation · Poster Presentation · Hepatology
NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US.
Read more →2023 · Abstract/Manuscript · Abstract/Manuscript
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.
Read more →2023 · Oral Presentation · Oral Presentation · Hepatology
Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study.
Read more →2022 · Poster Presentation · Poster Presentation · Hepatology
The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH.
Read more →2022 · Poster Presentation · Poster Presentation · Hepatology
Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks.
Read more →2022 · Abstract/Manuscript · Abstract/Manuscript
Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease.
Read more →2021 · Poster Presentation · Poster Presentation · Hepatology
Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from TARGET-NASH Study.
Read more →2021 · Abstract/Manuscript · Abstract/Manuscript
Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis.
Read more →2021 · Abstract/Manuscript · Abstract/Manuscript
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study.
Read more →2021 · Abstract/Manuscript · Abstract/Manuscript
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study.
Read more →2021 · Abstract/Manuscript · Abstract/Manuscript
Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort.
Read more →2020 · Poster Presentation · Poster Presentation · Hepatology
A Pragmatic Clinical Prognostic Classification Suitable for Universal Application Stratifies Patients with NAFLD by Risk of Mortality and Both Hepatic and Extrahepatic Outcomes.
Read more →2020 · Poster Presentation · Poster Presentation · Hepatology
Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice.
Read more →2020 · Poster Presentation · Poster Presentation · Hepatology
Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study.
Read more →2020 · Poster Presentation · Poster Presentation · Hepatology
Predicting advanced fibrosis using non-invasive clinical tests and modern machine learning methods in TARGET-NASH.
Read more →2020 · Abstract/Manuscript · Abstract/Manuscript
Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease.
Read more →2020 · Abstract/Manuscript · Abstract/Manuscript
Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases.
Read more →2020 · Oral Presentation · Oral Presentation · Hepatology
Clinical Profile of Nonalcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Mellitus.
Read more →2020 · Oral Presentation · Approval & Commercialization · Hepatology
Weight Loss and Change in Alanine Aminotransferase (ALT) Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) Receiving Standard Care in Real World Clinical Practice: TARGET-NASH.
Read more →2019 · Poster Presentation · Poster Presentation · Hepatology
Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort.
Read more →2019 · Poster Presentation · Poster Presentation · Hepatology
Patient Reported Outcomes Among Pediatric Patients with Nonalcoholic Fatty Liver Disease: TARGET-NASH.
Read more →2019 · Poster Presentation · Poster Presentation · Hepatology
Patterns of Medication Use Among Adult Patients with Elevated Serum ALT Levels in Patients with NAFLD: TARGET-NASH.
Read more →2019 · Poster Presentation · Poster Presentation · Hepatology
The Prescribing Patterns and Use of Statins in Patients with Nonalcoholic Fatty Liver Disease.
Read more →2019 · Poster Presentation · Poster Presentation · Hepatology
Opioid use in patients with NAFLD: prevalence and association with comorbidities and disease severity.
Read more →2019 · Poster Presentation · Poster Presentation · Hepatology
Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD.
Read more →2019 · Oral Presentation · Oral Presentation · Hepatology
Incidence of Achieving Weight Loss Goals in Usual Clinical Practice: Results for the TARGET-NASH Observational Cohort.
Read more →2018 · Poster Presentation · Poster Presentation · Hepatology
Characterization of polypharmacy in patients with NAFLD.
Read more →2018 · Poster Presentation · Poster Presentation · Hepatology
Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) with and without Type 2 Diabetes Mellitus (T2DM).
Read more →2018 · Poster Presentation · Poster Presentation · Hepatology
Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH.
Read more →2018 · Poster Presentation · Approval & Commercialization · Hepatology
Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease.
Read more →2017 · Poster Presentation · Poster Presentation · Hepatology
Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH.
Read more →2017 · Poster Presentation · Care · Hepatology
Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH.
Read more →2017 · Abstract/Manuscript · Abstract/Manuscript
Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET-NASH study.
Read more →
